Early-career researchers, join vibrant discussions and connect with global leaders at Tumor Immunology Meets Oncology! Hosted by Brandenburg Medical School Theodor Fontane in collaboration with SITC, May 7–9 in Germany. Learn more: https://ow.ly/RLo450YyIiB

The rationale for targeting nectin-4 in pancreatic cancer Nectin-4 is an immunoglobulinlike cell adhesion molecule that contributes to tumor aggressiveness and immune evasion in pancreatic ductal adenocarcinoma (PDAC). Its high and selective expression on pancreatic cancer cells, together with the clinical efficacy of nectin-4-targeted antibody–drug conjugates in other solid tumors, establishes nectin-4 as a compelling therapeutic target in PDAC.

The rationale for targeting nectin-4 in pancreatic cancer

Excited to share our article in @cp-trendscancer.bsky.social ‘The rationale for targeting nectin-4 in pancreatic cancer‘.
Read more about the significance of #nectin-4 in #PDAC and what’s on the horizon:
www.sciencedirect.com/science/arti...
#PancreaticCancer #NEC4NEOP

Three inspiring days at the Annual Meeting of the German Pancreas Club in Freiburg #DPC2026 have come to an end. As always, once DPC is over, we are already looking forward to the next one #DPC2027:
📍 Dresden, Germany
🗓️ March 4-6, 2027
www.dpc-conference.de
#DPC #PancreasResearch #Pancreatology

This issue’s cover features work by @seifertlab.bsky.social and team on Nectin-4’s link to poor outcome & immune suppression in patients with PDAC, and targeting Nectin-4 with an antibody-drug conjugate inhibited tumor growth in PDAC organoids: doi.org/10.1172/jci.insight.194290

We thank @insight.jci.org for highlighting our study on the cover of the current issue. Discover how #Nectin4 plays a crucial role in #PancreaticCancer and its potential implications for treatment: insight.jci.org/articles/vie...

New publication in @insight.jci.org! 🎉 We uncover a key role for #Nectin-4 in #PancreaticCancer, opening the door to new therapeutic strategies.

Read the full paper here: insight.jci.org/articles/vie...

Stay tuned — our multicenter phase II clinical trial #NEC4NEOP is coming next year! 🔬✨

Intratumoral regulatory T cells are associated with treatment response to neoadjuvant chemotherapy and prognosis in gastroesophageal adenocarcinoma Gastroesophageal junction (GEJ) adenocarcinoma is an increasingly common cancer with complex biology and poor prognosis. The treatment strategy for locally advanced tumors involves multimodal treat...

Excited to share our new publication in OncoImmunology! 🎉 We explore the association of intratumoral regulatory T cells with treatment response to neoadjuvant chemotherapy and prognosis in #GastroesophagealAdenocarcinoma. Read the full paper here: doi.org/10.1080/2162...

The Department of Visceral, Thoracic, and Vascular Surgery at the Carl Gustav Carus University Hospital is hosting a #WorldPancreaticCancerDay Symposium:
📅 Thursday 20 Nov | 5:00 - 8:00pm
📍 Albertinum
ℹ️ Open to everyone with an interest in pancreatic cancer: weltpankreaskrebstag.de/veranstaltun...

Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancer Current biomarkers for diagnosis and prognosis prediction in gastric (GC) and gastroesophageal junction (GEJ) cancer have limited accuracy, and the role of soluble immune checkpoints is unknown. In th...

Excited to announce a new publication from the @seifertlab.bsky.social identifying soluble TIM-3 and Galectin-9 as novel biomarkers in #GastricCancer and #GastroesophagealAdenocarcinoma. Out today in @cp-iscience.bsky.social: www.cell.com/iscience/ful...

Congratulations to Dr. David Digomann, research fellow in the @seifertlab.bsky.social , on receiving the AIO scholarship for #ESMO25. David will also present his latest work, showcasing a novel biomarker for #GastricCancer in a poster presentation - soon to be published.

Please join us at the Dresden Immunology Seminar Series

Celebrating the 10-year anniversary of the Seifert Lab at University Hospital Dresden and NCT Dresden with a fantastic lab retreat. Grateful for this remarkable team!

Join us at #GI26 to learn about the latest diagnostic and therapeutic strategies in GI cancers to transform your patient outcomes in a program planned by and featuring multidisciplinary experts.

Register today: brnw.ch/21wV49s

The evolution of cancer cells decoded Cancer does not develop overnight. It can take decades for cancer-promoting changes in the genome to eventually lead to the formation of a malignant tumor. Researchers at the German Cancer Research Ce...

#Cancer does not develop overnight. Researchers at the DKFZ have now developed a method that allows for the first time to reconstruct the evolution of cancerous cells from a single tissue sample.

t1p.de/1jfo4

Are you looking to start your #lab in a fantastic scientific 🧪environment, with great colleagues, and in a spectacular place to live?

Then check out our open #junior #faculty position at the Department of Oncology, University of Lausanne, Switzerland:
www.unil.ch/dof/en/home/...

⏰ Deadline 27 June

AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research - Emerging Science Driving Transformative Solutions Meeting overview details for AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research - Emerging Science Driving Transformative Solutions

www.aacr.org/meeting/aacr...
Abstracts and award applications are due July 15. See you in Boston Sep 28 to Oct 1. @theaacr.bsky.social #PancreaticCancer #2025

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer | NEJM Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but recurrence rates remain hig...

MATTERHORN manuscript published today in the New England Journal of Medicine. #ASCO25 www.nejm.org/doi/full/10....

More news from #ASCO25 Plenary! MATTERHORN results: Perioperative durvalumab/FLOT shows superior EFS over placebo/FLOT in early-stage, resectable G/GEJ cancer: brnw.ch/21wT4R8
#ASCODailyNews #GICSM

Submit your abstract to #CICON25 in #Utrecht and present your research as poster or short talk: cancerimmunotherapyconference.org

Novel ICI–TKI combination outplays sorafenib in advanced HCC First-line treatment with anlotinib plus penpulimab significantly improves the outcomes of patients with unresectable hepatocellular carcinoma relative to sorafenib.

#MedNews - First-line treatment with #anlotinib plus #penpulimab significantly improves the outcomes of patients with unresectable hepatocellular carcinoma relative to #sorafenib.

Full story 👉 buff.ly/aA3W8IV

#OncSky #HCC

🚨 FOLFIRINOX vs. GEM Nab Paclitaxel for LAPC @ascocancer.bsky.social

💉 171 pts median PFS 9 months better in FOLFIRINOX group

🎯 FOLFIRINOX improves PFS significantly compared with gemcitabine and is well tolerated in LAPC

ascopubs.org/doi/10.1200/...

Well deserved! Congrats!

Figure showing most common symptoms and signs of pancreatic cancer at diagnosis. Copyright: Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Pancreatic cancer, often linked to smoking, obesity and diabetes, is predicted to become the 2nd leading cause of cancer-related death by 2030.

A recent Seminar discusses the need for novel therapies & future directions for research: tinyurl.com/ywue2nfs

Apply to DKFZ Marie Skłodowska Curie MasterClasses

Do you want to do your #postdoc in #cancerresearch with the most prestigious #fellowship in Europe? Apply to DKFZ Marie Skłodowska Curie MasterClasses by May 19. Projects in #cellandmolecularbiology #genomics #bioinformatics #immunology #medicaltechnology, #epidemiology.
Apply here: t1p.de/nx6tu

🚨New publication! 🚨

A new method for evaluating CA19-9 during neoadjuvant therapy, and its role in predicting overall and disease-free survival in BR-PC. A way towards personalised prognostication! 💜💪🏻🙏🏼

doi.org/10.1097/SLA....

Neoadjuvant chemo 🤜🤛 surgery for Resectable PDAC 🇯🇵 RCT

💉 Gemcitabine + S1 median OS 37 months vs. 26

💡 Is neoadjuvant chemo extending survival over upfront surgery?!

🤔 What are your thoughts?! 💭

journals.lww.com/annalsofsurg...

#HPBSky #Surgsky

English The German Cancer Congress is the oldest, most important and largest scientific congress on oncology in German-speaking countries.

📌 Save the date: The next German #Cancer #Congress will take place from February 18 - 21, 2026. The website is now online: www.deutscher-krebskongress.de/english

200 #scholarships are available for students & certain professionals! All information can be found at: t1p.de/hi414

#DKK2026 #MedSky

Now online in Cancer Discovery: Cytosolic Phospholipase A2 Determines Intercellular Heterogeneity of Stress Granules and Chemotherapy Response - by Alexandra Redding, Elda Grabocka, and colleagues doi.org/10.1158/2159...

Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial - Nature Medicine Exploratory biomarker analyses of the phase 3 CheckMate 649 trial show that in patients with advanced gastroesophageal cancer, KRAS alterations were associated with greater overall survival (OS) benef...

Congrats to Yelena Janjigian and team on their study in @naturemedicine.bsky.social, which presented biomarker analysis of nivolumab plus chemotherapy or ipilimumab in #gastroesophagealcancer. @mskcancercenter.bsky.social
www.nature.com/articles/s41...